Expression analysis of potential novel biomarkers TRIM29 alongside lncRNA NORAD and MIR497-HG in breast, gastric, and colorectal cancers

@article{sharifi2026expression,
  title = {{Expression analysis of potential novel biomarkers TRIM29 alongside lncRNA NORAD and MIR497-HG in breast, gastric, and colorectal cancers}},
  author = {Nafiseh Sharifi and Pooria Parvaz and Danial Khezrian and Behnaz Saeidi Palomi and Niloofar Nasr Esfahani and Helia Ebrahimi and Ghazal Delgoshae and Erfan Dehghan and Sayedeh Zahra Shirdeli and Mohammad Rezaei and Mansoureh Azadeh and Reza Rasoolzadeh},
  journal = {Molecular genetics and metabolism reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.ymgmr.2026.101370},
  url = {https://europepmc.org/article/PMC/PMC13717741},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - Expression analysis of potential novel biomarkers TRIM29 alongside lncRNA NORAD and MIR497-HG in breast, gastric, and colorectal cancers
AU  - Nafiseh Sharifi
AU  - Pooria Parvaz
AU  - Danial Khezrian
AU  - Behnaz Saeidi Palomi
AU  - Niloofar Nasr Esfahani
AU  - Helia Ebrahimi
AU  - Ghazal Delgoshae
AU  - Erfan Dehghan
AU  - Sayedeh Zahra Shirdeli
AU  - Mohammad Rezaei
AU  - Mansoureh Azadeh
AU  - Reza Rasoolzadeh
PY  - 2026
DA  - 2026/10/20
JO  - Molecular genetics and metabolism reports
DO  - 10.1016/j.ymgmr.2026.101370
UR  - https://europepmc.org/article/PMC/PMC13717741
AB  - Background  The rising cancer incidence and mortality rates support continued investigation of molecular markers in breast cancer (BC), gastric cancer (GC), and colorectal cancer (CRC). mRNAs and lncRNAs are involved in cancer-related regulation, and altered expression of TRIM29, NORAD, and MIR497HG has been reported in different tumor types. This study evaluated these three transcripts as candidate diagnostic biomarkers in BC, GC, and CRC using public expression datasets and RT-qPCR validation.Methods  Bioinformatics and RT-qPCR analyses showed cancer type-specific expression patterns. MIR497HG was downregulated in BC, GC, and CRC in both public-data analysis and RT-qPCR validation. NORAD was significantly upregulated in GC and CRC, while its change in BC was not significant by RT-qPCR. TRIM29 was downregulated in BC and upregulated in CRC by RT-qPCR. In GC, GEO microarray analysis and RT-qPCR supported TRIM29 downregulation, while ENCORI analysis suggested upregulation, indicating dataset-dependent differences. ROC analysis supported the diagnostic potential of these transcripts in a cancer type-specific manner.Results  Bioinformatics and RT-qPCR analyses revealed TRIM29 was downregulated in BC and upregulated in CRC, but It reduced in GC despite microarray data suggesting otherwise. TRIM29 showed significant interaction with hsa-miRNA-3940-5p. MIR497HG expression was notably reduced in BC, GC, and CRC across both microarray and RT-qPCR. It also exhibited strong links with MUC2, MUC4, MUC5AC, and MUC5B. While ENCORI indicated a slight decrease in NORAD expression in BC, qRT-PCR results were not significant. However, NORAD was significantly upregulated in GC and CRC, interacting with key cancer-related genes like MUC4, MUC2, MUC16, MUC3A, and MUC5AC.Conclusion  The findings support TRIM29, NORAD, and MIR497HG as candidate diagnostic biomarkers in GC and CRC, while TRIM29 and MIR497HG showed diagnostic relevance in BC. Pathway enrichment suggested a possible association between TRIM29-related genes and interferon-related signaling, but this result requires functional validation. The observed correlations between TRIM29 and the lncRNAs MIR497HG and NORAD should be interpreted as co-expression patterns and not as evidence of direct molecular interaction.
SN  - 2214-4269
ER  -